ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Daewoong Pharma (069620.KO)
Daewoong Pharma stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · Korea Exchange (KOSPI) · South Korea
₩99,100▼ -1.49%
Prices as of Oct 27, 2026 · KRW
Chance of rising in 1 month
49%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Daewoong Pharma in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Daewoong Pharma
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Daewoong Pharma a 49% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₩91,734 and ₩106,610; in 9 out of 10, between ₩80,292 and ₩121,801. Estimated annual volatility is 44%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- ₩1.2T
- Market cap (USD)
- $900M
- P/E ratio
- 6.2
- Dividend yield
- 0.57%
- 52-week high
- ₩199,400
- 52-week low
- ₩98,600
- Revenue (12 months)
- ₩1.6T
- Gross margin
- 52.3%
- Operating margin
- 15.2%
- Net margin
- 12.0%
- Beta
- 0.00
What this means
ATLAS does not publish a fair value for 069620.KO right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks 069620.KO has traded between ₩98,600 and ₩199,400. Today it is 50.3% below that high and 1% above its low.
On the business: net margin is 12.0%; it trades at 6.2 times earnings.
Its beta is 0.00: it tends to move less than the market.
About the company
Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally.
Want to see everything about Daewoong Pharma?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Daewoong Pharma do?
Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally.
What is the chance 069620.KO goes up next month?
49%: close to a coin flip. In half of the simulated outcomes, 069620.KO ends the month between ₩91,734 and ₩106,610.
How big is Daewoong Pharma and what is its P/E ratio?
Daewoong Pharma's market capitalization is ₩1.2T. Its price-to-earnings (P/E) ratio is 6.2: you pay ₩6.17 for each ₩1.00 of yearly earnings.
Does Daewoong Pharma pay a dividend?
Yes. 069620.KO's current dividend yield is 0.57% at today's price (₩99,100).
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer